Device provides direct access to human neuroanatomy, enabling the identification of biomarkers and mapping of neural networks
LAVALLE, WI / ACCESSWIRE / February 20, 2024 / Threshold NeuroDiagnostics, a stealth startup neural interface company, today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11904169 for the Medusa Electrode, the first manufactured device to bridge neuromodulation electrodes with neurodiagnostic equipment and complex algorithms like artificial intelligence. This FDA-registered Class II (exempt) product introduces enhanced precision and accessibility to neural interface technology.
The Medusa Electrode transforms neuromodulation and neurodiagnostic research by translating manufacturer-specific neuromodulation connections into universal EEG plugs. This approach to neuro interface allows access to more than 70,000 invasive electrodes per year in the United States, making it a cost-effective solution for applications including anatomical localization, biomarker access, and expanding research opportunities. By converting specific plugs to universal 1.5 DIN connectors, it enables seamless integration between the human nervous system and neurophysiology equipment, enhancing both clinical applications and research possibilities. This universal electrode significantly improves medical professionals' access to Class III invasive neuromodulation electrodes, expanding neurodiagnostic capabilities.
"Our goal is to leverage the human neural network to address a broad spectrum of neurological issues, and securing this patent is a key milestone in that journey," stated Geoffrey Allott, B.A., CNIM, Founder of Threshold NeuroDiagnostics. "We aim to quickly evaluate hypotheses, analyze responses, and develop effective solutions, bypassing regulatory hold-ups, unnecessary expenses, and ethical issues. The Medusa Electrode is an integral step in creating "closed-loop" neuromodulation systems, similar to a 'nervous system pacemaker,' demonstrates our focus on creating simple and flexible solutions that have a profound impact on neuromodulation research and therapies."
The Medusa Electrode has demonstrated the ability to transform patient care and the understanding of neuroanatomy. This essential connection has allowed leading research centers to develop a cure for depression, reduce binge eating, treat obsessive compulsive disorders, and other psychiatric illnesses. In addition, the Medusa Electrode has been used to develop next generation neuroprosthetics that not only provide both sensory and motor control of artificial limbs, but also include neuromodulation assisted respiration devices. Last, the Medusa Electrode is being deployed for a wide variety of peripheral devices for gastrointestinal, hemodynamic, and bowel and bladder function.
By leveraging current neuromodulation technology and pivoting devices that are currently on the market, the company can substantially lower the cost of developing a wide range of neuromodulation products for underserved markets. The net effect of deploying the Medusa Electrode allows neuromodulation companies to diversify their markets, allows doctors a wide variety of solutions to treat patients, and delivers treatment to large segments of patients where treatment is cost prohibitive or not available.
Threshold NeuroDiagnostics is seeking partners to broaden the Medusa Electrode's applications and compatibility. The company invites neuromodulation manufacturers for collaboration to integrate the Medusa Electrode more widely in neural interface solutions, aiming to advance bioelectric medicine and neuromodulation therapy. Through industry partnerships, Threshold NeuroDiagnostics intends to fast-track the technology's adoption, improve neuromodulation device functions, and support neuroscientific research and patient care. For more information, please visit https://tndmed.co/.
About Threshold NeuroDiagnostics
Threshold NeuroDiagnostics is a brain-computer interface company. Leveraging FDA-approved products, the company aims to overcome regulatory, ethical, and financial barriers in neurotechnology, bringing solutions that transform the landscape of neuromodulation and neurodiagnostic practices. For more information about the Medusa Electrode and Threshold NeuroDiagnostics, please visit https://tndmed.co/.
Contact:
Sarah Thorson
[email protected]
SOURCE: Threshold NeuroDiagnostics